Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Modern Africa Today.
Press releases published on May 15, 2025
High Grade at Globex’s Carp Fluorspar Property, Nevada
GlobeNewswire
·
May 15, 2025
ROUYN-NORANDA, Quebec, May 15, 2025 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang …
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
GlobeNewswire
·
May 15, 2025
Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) …
Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform
GlobeNewswire
·
May 15, 2025
WARSAW, Poland, May 15, 2025 (GLOBE NEWSWIRE) -- Member States are nearing the end of discussions on EU pharmaceutical reform to ensure affordable medicines and support EU manufacturing in Europe. This will enhance the Union’s strategic resilience and …
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
GlobeNewswire
·
May 15, 2025
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
GlobeNewswire
·
May 15, 2025
Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Continued momentum with completed patient enrollment for the 6-week interim analysis (n=24) …
CorMedix Inc. to Participate in the RBC Global Healthcare Conference
GlobeNewswire
·
May 15, 2025
BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the RBC …
New report urges governments to back the coexistence of used clothing imports and local manufacturing for African growth
EIN Presswire
·
May 15, 2025
New report forecasts 15-year roadmap for Kenyan growth, showing that Mitumba and domestic textile manufacturing are complementary sources of growth. NAIROBI, NAIROBI COUNTY, KENYA, May 15, 2025 /EINPresswire.com/ -- The Institute of Economic Affairs …
Reflect Scientific Advances Market Presence by Transitioning from OTCQB to OTCIQ
GlobeNewswire
·
May 15, 2025
OREM, Utah, May 15, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of innovative cryogenic technologies for the life sciences and biotech industries, today announced that it is actively transitioning from the OTCQB Venture …
Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
GlobeNewswire
·
May 15, 2025
In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash., May 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial …
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
GlobeNewswire
·
May 15, 2025
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic …
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
GlobeNewswire
·
May 15, 2025
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May …
Polpharma Group fordert dringende Maßnahmen zum Schutz eines frühzeitigen und gerechten Zugangs zu Medikamenten für europäische Patienten
GlobeNewswire
·
May 15, 2025
WARSCHAU, Polen, May 15, 2025 (GLOBE NEWSWIRE) -- Die Polpharma Group, ein führendes Pharmaunternehmen, fordert die Europäische Union nachdrücklich auf, entschlossene Maßnahmen zu ergreifen, um die Arzneimittelreform abzuschließen und die Kapazitäten …
Polpharma Group plaide en faveur d’une action urgente en vue de garantir aux patients européens un accès équitable et précoce aux médicaments
GlobeNewswire
·
May 15, 2025
VARSOVIE, Pologne, 15 mai 2025 (GLOBE NEWSWIRE) -- Polpharma Group, acteur pharmaceutique de première importance, enjoint l’Union européenne à arrêter des mesures décisives pour finaliser la réforme du secteur pharmaceutique et renforcer la capacité du …
Skyharbour and JV Partner Orano to Commence Extensive Summer 2025 Drilling Program at Preston Uranium Project
GlobeNewswire
·
May 15, 2025
Vancouver, BC, May 15, 2025 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”), is pleased to announce that its joint-venture partner, Orano Canada Inc. (“Orano”), will commence a …
Avicanna Reports Q1 2025 Results and First Profitable Quarter
GlobeNewswire
·
May 15, 2025
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based …
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 15, 2025
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter …
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 15, 2025
PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales force PEMGARDA revenue re-acceleration observed in Q2 2025 to date Invivyd continues to …
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 15, 2025
Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate doses Encouraging …
Annual Report and Notice of Meeting
GlobeNewswire
·
May 15, 2025
Reykjavík, May 15, 2025 (GLOBE NEWSWIRE) -- (“Amaroq Minerals” or the “Company”) Annual Report and Notice of Meeting TORONTO, ONTARIO – May 15, 2025 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mining company with a substantial …
Verde Announces Q1 2025 Results
GlobeNewswire
·
May 15, 2025
(All figures are in Canadian dollars, unless stated otherwise. Average exchange rate in Q1 2025: C$1.00 = R$3.93) SINGAPORE, May 15, 2025 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) ("Verde” or the “Company”) announces its financial results for the …